<i>MBD4</i> deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients: A retrospective study.
Mathilde Saint‐Ghislain(Inserm), Manuel Rodrigues(Inserm), Nathalie Cassoux(Université Paris Cité), Vincent Servois(Institut Curie), Pascale Mariani(Institut Curie), Sylvie Négrier(Centre Léon Bérard), Thierry Lesimple, Raymond L. Barnhill(Université Paris Cité), Alexandre Matet(Fondation Asile des Aveugles), Sophie Gardrat(Université Paris Sciences et Lettres), Nicolas Penel(Centre Oscar Lambret), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Yannick Le Corre(Université Nantes Angers Le Mans), Lauris Gastaud(Heidelberg University), Lionnel Geoffrois(Institut de Cancérologie de Lorraine), Toulsie Ramtohul(Université Paris Sciences et Lettres), Jean Emmanuel Kurtz(Institut de Cancérologie Strasbourg), Sophie Piperno‐Neumann(Institut Curie)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k